<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03998696</url>
  </required_header>
  <id_info>
    <org_study_id>BSMMU/2017/1577</org_study_id>
    <secondary_id>2017/311</secondary_id>
    <nct_id>NCT03998696</nct_id>
  </id_info>
  <brief_title>An Experimental Study to Compare Treatment Response and Toxicities of Concurrent Chemoradiation With Weekly Cisplatin and Three Weekly Cisplatin in Locally Advanced Head and Neck Cancer.</brief_title>
  <acronym>HNC</acronym>
  <official_title>Comparison Between Two Regimens of Chemotherapy Concurrent With Radiotherapy in Locally Advanced Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare treatment responses and toxicities of concurrent
      chemo-radiation with weekly and three weekly Cisplatin in locally advanced Head &amp; Neck
      Cancer. Half of the participants received Cisplatin (40 mg/m2) weekly with radiotherapy,
      while the other half received Cisplatin (100 mg/m2) thrice weekly with radiotherapy.
      Radiotherapy continued five days per week for six and half weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Loco-regional tumor control after completion of treatment</measure>
    <time_frame>6 months</time_frame>
    <description>Response Evaluation Criteria in Solid Tumors was used to measure outcome:
Complete response (CR): Disappearance of all target lesions.
Partial response (PR): At least a 30% decrease in the sum of diameters of target lesions.
Progressive disease (PD): At least a 20% increase in the sum of diameters of target lesions.
Stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment related toxicities during and after treatment</measure>
    <time_frame>8 months</time_frame>
    <description>National Cancer Institute's Common Terminology Criteria for Advanced Events (version 4.03) was used measure toxicities.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Weekly Cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inj. Cisplatin 40 mg /m2 intravenous infusion delivered concurrently with radiotherapy on a weekly basis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Three weekly Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inj. Cisplatin 100 mg/m2 intravenous infusion delivered on a three weekly basis on days 1, 22 and 43 delivered concurrently with radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin 40 mg/m2</intervention_name>
    <description>Cisplatin 40 mg/m2, weekly, concurrent with Radiotherapy</description>
    <arm_group_label>Weekly Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin 100 mg/m2</intervention_name>
    <description>Cisplatin 100 mg/m2, three weekly, concurrent with Radiotherapy</description>
    <arm_group_label>Three weekly Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proved, previously untreated, Squamous cell carcinoma of head &amp; neck

          -  Stages III to IVB

        Exclusion Criteria:

          -  Patients with history of prior chemotherapy or radiotherapy to the head and neck
             region.

          -  Initial surgery (excluding diagnostic biopsy) of the primary site.

          -  Patients with synchronous primaries.

          -  Those who are not willing to be included in the study.

          -  Pregnant or lactating woman.

          -  Serious medical illness

          -  Prisoners.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarwar Alam, MBBS, Mphil</last_name>
    <role>Study Chair</role>
    <affiliation>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bangabandhu Sheikh Mujib Medical University</name>
      <address>
        <city>Dhaka</city>
        <zip>1000</zip>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <link>
    <url>http://gco.iarc.fr/today/fact-sheets-populations</url>
    <description>Global Cancer Observatory (GLOBOCAN), 2018.</description>
  </link>
  <link>
    <url>http://www.who.int/gho/ncd/en</url>
    <description>Global Health Observatory (GHO) data, WHO, 2018.</description>
  </link>
  <reference>
    <citation>Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003 Jan 1;21(1):92-8.</citation>
    <PMID>12506176</PMID>
  </reference>
  <reference>
    <citation>Geeta SN, Padmanabhan TK, Samuel J, Pavithran K, Iyer S, Kuriakose MA. Comparison of acute toxicities of two chemotherapy schedules for head and neck cancers. J Cancer Res Ther. 2006 Jul-Sep;2(3):100-4.</citation>
    <PMID>17998687</PMID>
  </reference>
  <reference>
    <citation>Guan J, Zhang Y, Li Q, Zhang Y, Li L, Chen M, Xiao N, Chen L. A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus concurrent radiotherapy (CRT) for advanced head and neck cancer (HNC). Oncotarget. 2016 Oct 25;7(43):70185-70193. doi: 10.18632/oncotarget.11824.</citation>
    <PMID>27602493</PMID>
  </reference>
  <reference>
    <citation>Ho KF, Swindell R, Brammer CV. Dose intensity comparison between weekly and 3-weekly Cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: a retrospective comparison from New Cross Hospital, Wolverhampton, UK. Acta Oncol. 2008;47(8):1513-8. doi: 10.1080/02841860701846160.</citation>
    <PMID>18607863</PMID>
  </reference>
  <reference>
    <citation>Jacinto JK, Co J, Mejia MB, Regala EE. The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): a systematic review and meta-analysis. Br J Radiol. 2017 Nov;90(1079):20170442. doi: 10.1259/bjr.20170442. Review.</citation>
    <PMID>29053029</PMID>
  </reference>
  <reference>
    <citation>Lee JY, Sun JM, Oh DR, Lim SH, Goo J, Lee SH, Kim SB, Park KU, Kim HK, Hong DS, Kim JS, Kim SG, Yi SY, Yun HJ, Hyun MS, Kim HJ, Jung SH, Park K, Ahn YC, Ahn MJ. Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02). Radiother Oncol. 2016 Feb;118(2):244-50. doi: 10.1016/j.radonc.2015.11.030. Epub 2015 Dec 17.</citation>
    <PMID>26705681</PMID>
  </reference>
  <reference>
    <citation>Tsan DL, Lin CY, Kang CJ, Huang SF, Fan KH, Liao CT, Chen IH, Lee LY, Wang HM, Chang JT. The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity. Radiat Oncol. 2012 Dec 18;7:215. doi: 10.1186/1748-717X-7-215.</citation>
    <PMID>23245290</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 22, 2019</study_first_submitted>
  <study_first_submitted_qc>June 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2019</study_first_posted>
  <last_update_submitted>June 26, 2019</last_update_submitted>
  <last_update_submitted_qc>June 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</investigator_affiliation>
    <investigator_full_name>Dr. Ishtiaq-Ur-Rahim</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Locally advanced</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>Concurrent</keyword>
  <keyword>Weekly Cisplatin</keyword>
  <keyword>Three weekly Cisplatin</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_access_criteria>To request an electronic copy send email to dr.iurahim@gmail.com</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

